Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...

In a report released today, Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNY – Research Report). The ...